Daiichi Sankyo Authorizes the First YESCARTA (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan – Business Wire
stemadminAdult Stem CellsNo comments

SANTA MONICA, Calif. & TOKYO--(BUSINESS WIRE)--Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that YESCARTA (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, will be available to patients with relapsed or refractory large B-cell lymphomas in Japan through the first treatment center now authorized by Daiichi Sankyo. Kite and Daiichi Sankyo will also build on the exclusive licensing deal for commercialization rights for axicabtagene ciloleucel in Japan, formalized in January 2017.

Read more
ESSENT BIOLOGICS AND AMNION FOUNDATION PARTNER TO PROVIDE GERMINAL-ORIGIN CELLS TO FURTHER DRUG DISCOVERY AND REGENERATIVE MEDICINE RESEARCH – Yahoo…
stemadminAdult Stem CellsNo comments

Distribution Agreement Will Allow Access to Innovative Full-Term Placenta-Derived Cells to Support Ground-Breaking Research CENTENNIAL, Colo., Dec. 14, 2021 /PRNewswire/ -- Essent Biologics, a leading supplier of adult human-derived cell and scaffold materials, today announced it has entered into a global distribution partnership agreement with the Amnion Foundation, a non-profit cell bank specializing in birth-tissue related cells and services

Read more
Build Blood Better: New cell line is capable of giving rise to red blood cells outside the body – EurekAlert
stemadminAdult Stem CellsNo comments

image:Hematopoietic stem cells isolated from various sources such as bone marrow and umbilical cord blood are differentiated to erythroblasts, immature red blood cells that still hold a nucleus. These cells are then transduced with virus expressing HPV-E6/E7 to be immortalized. Established cell lines can be easily maintained and expanded infinitely

Read more
No Improvement in EFS for Aggressive B-cell NHL Noted With Second-line Tisagenlecleucel – Cancer Network
stemadminAdult Stem CellsNo comments

Findings from the phase 3 BELINDA trial (NCT03570892) that were presented during a press briefing at the 63rd American Society of Hematology Annual Meeting & Expositionrevealed that second-line tisagenlecleucel (Kymriah) did not improve event-free survival (EFS) vs standard of care (SOC) platinum-based chemotherapy followed by autologous stem cell transplant (ASCT) in aggressive B-cell non-Hodgkin lymphoma (NHL).

Read more
-Thalassemia Patients Go Transfusion-Free With Gene Therapy – MedPage Today
stemadminAdult Stem CellsNo comments

ATLANTA -- Patients with transfusion-dependent -thalassemia (TDT) who received a gene therapy achieved normal or near-normal levels of total hemoglobin and transfusion independence, with stable iron markers, according to long-term follow-up study results presented here. Of 57 patients who participated in four trials evaluating betibeglogene autotemcel (beti-cel) with a combined median follow-up of 41.5 months, 46 achieved transfusion independence, defined as no longer needing red blood cell transfusions for at least 12 months while maintaining a weighted average hemoglobin of at least 9 g/dL, reported Alexis Thompson, MD, MPH, of the Ann & Robert H. Lurie Children's Hospital of Chicago

Read more
Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye – PRNewswire
stemadminAdult Stem CellsNo comments

ZRICH, Switzerland, Dec. 13, 2021 /PRNewswire/ -- Rejuveron Life Sciences AG, a Zrich-based biotechnology company developing technologies for healthy aging, today announced that it has strengthened its support to a near-majority holding in Endogena Therapeutics Inc.,an endogenous regenerative therapeutics company. Rejuveron has funded a further $20m in the $29 million series A financing round to enable Endogena to progresstreatments targeting degenerative diseases of the eye.

Read more

Theme: Illdy.